ATC Group: J04AK06 Delamanid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04AK06 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J04 Antimycobacterials
3 J04A Drugs for treatment of tuberculosis
4 J04AK Other drugs for treatment of tuberculosis
5 J04AK06

Active ingredients in J04AK06

Active Ingredient Description
Delamanid

The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity.

Related product monographs

Title Information Source Document Type  
DELTYBA Dispersible tablet European Medicines Agency (EU) MPI, EU: SmPC
DELTYBA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.